A study to assess the role of vericiguat in the cardio-pulmonary pathophysiology in worsening heart failure with reduced ejection fraction (REVOLUT- HFrEF): preliminary results at 3 months follow up
Event:
ESC Congress 2025
Topic:
Heart Failure with Reduced Ejection Fraction (HFrEF)
Session:
Novel insights into heart failure therapy